Compare Ascendis Pharma A/S (ASND) vs Select Medical Holdings Corporation (SEM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Select Medical Holdings Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B). The key difference: Ascendis Pharma A/S is far larger — about 8.7× Select Medical Holdings Corporation's market cap, and Select Medical Holdings Corporation pays a 1.51% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SEM | |
|---|---|---|
Market Cap | $17.74B | $2.05B |
Sector | Health | Health |
52-Week High | $277.18 | $16.66 |
52-Week Low | $163.32 | $11.77 |
Enterprise Value | $18.11B | $5.01B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Select Medical Holdings (SEM) trades at $16.51, unchanged on the day, following the company's recent acquisition by a consortium led by Robert A. Ortenzio at $16.50 per share. The stock shows mixed technical signals with a bullish overall trend but bearish moving averages. Fundamentally, the company reported $5.45B revenue for 2025 with a 2.42% net margin, while valuation metrics appear reasonable with a P/E of 15.43 and P/S of 0.36. Recent earnings have been mixed with one beat and two misses against expectations.
The investment outlook is dominated by the completed acquisition, effectively capping upside near the current price. While fundamentals show stable operations with positive cash flow from operations, multiple law firms are investigating potential fiduciary breaches in the buyout process. Analyst sentiment is mixed with 35.7% buy ratings, but the acquisition removes typical growth catalysts. Key risks include legal challenges to the merger terms and execution risks during the ownership transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Select Medical Holdings Corporation
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →
